RxDoctor Payments Data

Kelly O'Connor, MD

Dermatology · Norwell, MANPI 1659875540

Payments from drug & device makers

$2,449in general payments, 2019–2025

Across 97 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$613
  • Johnson & Johnson$529
  • Sanofi$262
  • Novartis$236
  • UCB, Inc.$191
  • E.r. Squibb & Sons, L.L.C.$145
  • plus $473 from 7 others

What the payments were for

  • Food & beverage$2,34996%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,449 in reported general payments places this provider in the 60th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$242,805
Medicare patients
891
Services billed
2,596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$160,269
Cosentyx Unoready PenSecukinumab13$137,657
OtezlaApremilast18$94,268
Fluorouracil119$6,958
Metronidazole112$5,505
Fluocinonide52$2,497
Clobetasol Propionate27$2,341
Calcipotriene17$1,716
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc60$1,627
Ketoconazole73$1,544
Doxycycline Monohydrate64$1,006
Triamcinolone Acetonide63$968
Terbinafine Hcl38$565
Nystatin24$558
Tretinoin12$554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$529$160,26911 claims
AmgenOtezla$61$94,26818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 552 dermatology providers in Massachusetts.

Other dermatology in Norwell

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →